Gannex Pharma FXR Modulating Compound Patent US12600716B2
Summary
USPTO granted patent US12600716B2 to Gannex Pharma Co. Ltd. on April 14, 2026, for FXR-modulating compounds having a structure of formula (I), including pharmaceutically acceptable salts, esters, and stereoisomers. The patent contains 19 claims and covers therapeutic applications including liver disease (A61P 1/16), metabolic disorders, cardiovascular conditions, and kidney disease.
What changed
USPTO granted patent US12600716B2 to Gannex Pharma Co. Ltd. for compounds modulating FXR (Farnesoid X Receptor) activity. The patent covers formula (I) compounds as salts, esters, or stereoisomers with applications across multiple therapeutic areas including cholestatic liver diseases (A61P 1/16), antiviral infections (A61P 31/20), metabolic conditions (diabetes A61P 3/10, obesity A61P 3/04), cardiovascular diseases (A61P 9/10, A61P 9/12), and kidney disorders (A61P 13/02, A61P 13/08). The patent issued from application No. 17756789 filed October 12, 2020, with inventors Bailing Yang, Gudmundsson Kristjan, Liuyu Dong, and James Chen.
Gannex Pharma gains 20-year patent exclusivity from the October 2020 filing date, preventing competitors from making, using, or selling the patented FXR modulators without license. Competitors developing FXR-targeted therapeutics for covered indications must assess freedom-to-operate and potential design-around strategies. The patent's broad CPC classification (C07D 413/12, A61K 31/4439, A61P 1/16) suggests broad compound and use protection that may affect multiple drug development programs in the FXR agonist/antagonist space.
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compounds for modulating activity of FXR and uses thereof
Grant US12600716B2 Kind: B2 Apr 14, 2026
Assignee
Gannex Pharma Co. Ltd.
Inventors
Bailing Yang, Gudmundsson Kristjan, Liuyu Dong, James Chen
Abstract
Provided are a compound for modulating the activity of FXR having a structure of formula (I), a pharmaceutically acceptable salt, an ester or a stereoisomer thereof.
CPC Classifications
C07D 413/12 C07D 261/08 C07D 417/12 A61K 31/42 A61K 31/427 A61K 31/4439 A61K 31/496 A61K 31/501 A61K 45/06 A61K 31/497 A61P 1/16 A61P 31/20 A61P 3/00 A61P 3/04 A61P 3/10 A61P 9/00 A61P 9/10 A61P 9/12 A61P 13/02 A61P 13/08 A61P 3/06
Filing Date
2020-10-12
Application No.
17756789
Claims
19
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.